Politics · United States · 4 hrs ago
Missouri AG tells Eli Lilly to stop requiring hospital claims data for discounts
Missouri Attorney General Catherine Hanaway sent Eli Lilly a cease-and-desist letter over the company’s requirements for hospital drug discounts.
The federal 340B program lets eligible hospitals buy medicines at reduced prices from drug manufacturers.
Hanaway alleges that Eli Lilly required hospitals to submit detailed claims data for its products to receive those prices.
Her office says MU Health Care lost access to the discounts after refusing to provide the data, and the health system later shared it temporarily to regain access.
MU Health Care says it appreciates the attorney general’s efforts to protect patient privacy and its ability to care for patients.
Hanaway alleges the policy violates Missouri’s consumer protection law and says it could burden hospitals, including those serving rural communities.
The letter asks Eli Lilly to stop making claims data a condition of 340B prices.
Missouri Attorney General Catherine Hanaway sent Eli Lilly a cease-and-desist letter over its requirements for hospitals seeking 340B drug discounts.
Hanaway alleges Lilly required hospitals to submit detailed claims data to qualify for lower prices.
The attorney general’s office says MU Health Care lost access to 340B pricing after refusing to provide the data.
MU Health Care later provided the data temporarily to regain access and prevent further harm to patients, according to Hanaway.
The letter asks Lilly to stop requiring claims data for lower pricing under the federal program.
- Who
- Missouri Attorney General Catherine Hanaway sent the letter to Eli Lilly and Company.
- What
- Hanaway alleges Lilly unlawfully required claims data from hospitals seeking 340B discounts.
- When
- Hanaway announced the letter on Monday, October 26, 2026.
- Where
- Missouri.
- Why
- Hanaway says the data requirements unlawfully conditioned hospitals’ access to lower drug prices.
This story does not have two clearly opposing sides.
Eli Lilly announced a policy requiring 340B entities to submit claims data for its products to qualify for reduced prices, according to the cease-and-desist letter.
MU Health Care was cut off from 340B pricing after refusing to provide the data, according to the attorney general’s office.
MU Health Care temporarily provided Lilly with the data to regain access, according to the attorney general’s office.
Hanaway announced that her office had sent Lilly a cease-and-desist letter.
- Attorney general
- Catherine Hanaway
- Company
- Eli Lilly and Company
- Program
- Federal 340B Drug Pricing Program
- Affected health system
- MU Health Care
- Missouri law cited
- Missouri Merchandising Practices Act
3 sources
What people are saying
Big Pharma does not get to bully Missouri hospitals or hold prescription drug prices hostage
By representing that covered entities may purchase drugs at federally required 340B prices while simultaneously denying those prices to Missouri hospitals that refuse to provide unnecessary claims data, Lilly misled consumers and used its market position to force unlawful conditions on Missouri healthcare providers
We appreciate the Missouri Attorney General's efforts to protect patient privacy and preserve our ability to provide high-quality care to all patients.